Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Reign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000757 47 linked products · source seen 9 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx47product presentations
G22generic molecules
DF6dosage-form groups
TA6therapeutic areas
PKR47current price records
REG40registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 2026Anti-infectives31 · 66%Pain & musculoskeletal5 · 11%Vitamins, minerals & nutrition5 · 11%Respiratory & allergy2 · 4%Gastrointestinal & hepatology2 · 4%Fluids & supportive care2 · 4%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 202647presentationsTablet21 · 45%Suspension10 · 21%Injection5 · 11%Capsule4 · 9%Syrup4 · 9%Sachet3 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 202644comparable productsBelow market median12 · 27%Near market median28 · 64%Above market median4 · 9%Company median price position-0.1%Lowest-price equivalents2Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 2026Semos Pharmaceuticals PVT LTD19 shared86% overlapNabiqasim Industries (Pvt) Ltd.,18 shared82% overlapBosch Pharmaceuticals (Pvt) Ltd.17 shared77% overlapNeutro Pharma (Pvt.) Ltd.,17 shared77% overlapMediate Pharmaceutical Pvt Ltd16 shared73% overlapZafa Pharmaceutical Laboratories (P…16 shared73% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives31 products · 66%
Pain & musculoskeletal5 products · 11%
Vitamins, minerals & nutrition5 products · 11%
Respiratory & allergy2 products · 4%
Gastrointestinal & hepatology2 products · 4%
Fluids & supportive care2 products · 4%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials8 products · 17%
Third-generation cephalosporins8 products · 17%
Antimalarials7 products · 15%
Analgesics / NSAIDs5 products · 11%
Vitamins / minerals / hematinics5 products · 11%
Macrolide antibacterials4 products · 9%
Antihistamines2 products · 4%
Antifungals2 products · 4%
Formulation footprint

Dosage forms

Tablet21 products
Suspension10 products
Injection5 products
Capsule4 products
Syrup4 products
Sachet3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 RenfloxCiprofloxacin 5presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet #2 NuprinIbuprofen 3presentations 100 mg/5 mL · Suspension #3 REFTOXCefotaxime 3presentations 1 g, 250 mg, 500 mg · Injection #4 RenzithAzithromycin 3presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Tablet #5 AndinLoratadine 2presentations 10 mg, 5 mg/5 mL · Tablet, Syrup #6 DumolParacetamol 2presentations 120 mg/5 mL · Syrup
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1227% of comparable products
Near market median28within ±5% of median
Above market median49% of comparable products
Lowest-price equivalents2ties included
Company median price position -0.1% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Rentanic 150 mg + 0.5 mgFerrous sulfate + Folic acid · Tablet · 1000's PKR 0.95/tablet-40.1% vs market median Renflu 150 mgFluconazole · Tablet · 1's PKR 130.21/tablet-29.3% vs market median Rezo-lid 400 mgLinezolid · Tablet · 12's PKR 176.03/tablet-23.9% vs market median Renflox 250 mg/5 mLCiprofloxacin · Dry suspension · 120ml PKR 3.80/mL-22.9% vs market median Andin 10 mgLoratadine · Tablet · 10's PKR 10.83/tablet-22.6% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Semos Pharmaceuticals PVT LTD103 products · 45 generics 19shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 18shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 17shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 17shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 16shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 16shared generics
Regulatory & price activity

Observed database signals

Registration numbers40
Price-history records54
Products with price history6
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

31 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
C-Throcin Clarithromycin 125 mg/5 mL Dry suspension 60ml 073800 PKR 423.88 PKR 7.06/mL Near median
Gnate Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 073794 PKR 501.81 PKR 62.73/tablet Near median
Gnate Artemether + Lumefantrine 40 mg + 240 mg Tablet 10's 073794 PKR 589.25 PKR 58.93/tablet 8% below median
Gnate DS Artemether + Lumefantrine 80 mg + 480 mg Tablet 4's 073795 PKR 418.17 PKR 104.54/tablet Near median
Largimox Moxifloxacin 400 mg Tablet 5's 073791 PKR 902.88 PKR 180.58/tablet Near median
Lesil Levofloxacin 500 mg Tablet 10's 073793 PKR 790.73 PKR 79.07/tablet Near median
Lesil Levofloxacin 250 mg Tablet 10's 097117 PKR 475.20 PKR 47.52/tablet Near median
Loczole Fluconazole 150 mg Capsule 1's 073797 PKR 262.32 PKR 262.32/capsule Near median
RAYFIX Cefixime 100 mg/5 mL Suspension 30ml 088953 PKR 285.13 PKR 9.50/mL 9% below median
RAYFIX Cefixime 400 mg Capsule 5's 088954 PKR 564.16 PKR 112.83/capsule Near median
RAYFIX DS Cefixime 200 mg/5 mL Dry suspension 30ml 088952 PKR 385.30 PKR 12.84/mL Near median
RECOTAX Ceftriaxone 500 mg Injection 1's 088948 PKR 323.14 PKR 323.14/vial/unit Near median
RECOTAX Ceftriaxone 1000 mg Injection 1's 088949 PKR 610.16 PKR 610.16/vial/unit Near median
REFTOX Cefotaxime 500 mg Injection 1's 088950 PKR 159.25 PKR 159.25/vial/unit Near median
REFTOX Cefotaxime 250 mg Injection 1's 088951 PKR 105.67 PKR 105.67/vial/unit Near median
REFTOX Cefotaxime 1 g Injection 1's 088955 PKR 286.42 PKR 286.42/vial/unit Near median
Renchloro Chloroquine 250 mg Tablet 500's 104194 PKR 1,508.62 PKR 3.02/tablet 94% above median
Renchloro Chloroquine 50 mg/5 mL Syrup 60ml 104195 PKR 19.03 PKR 0.32/mL Near median
Renflox Ciprofloxacin 250 mg/5 mL Dry suspension 60ml 076474 PKR 304.13 PKR 5.07/mL Near median
Renflox Ciprofloxacin 500 mg Tablet 10's 073792 PKR 408.44 PKR 40.84/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.